Otsuka Pharmaceutical Development & Commercialization
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Otsuka Pharmaceutical Development & Commercialization sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).
Otsuka Pharmaceutical Development & Commercialization: 221 sponsored US clinical trials, 8 recruiting.
Otsuka Pharmaceutical Development & Commercialization sponsors 221 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 186 completed. 119 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 12 trials.
Top-decile sponsor footprint
Otsuka Pharmaceutical Development & Commercialization ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
186 of 208 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
221 total, page 3 of 5
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
NCT02251275
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
NCT02219009
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
NCT02196506
A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis
NCT02068352
This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.
NCT05015673
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
NCT02192554
A Phase 1 Study Comparing AVP-786 With AVP-923
NCT02336347
A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
NCT02144415
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
NCT02160145
Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
NCT02091882
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
NCT02050854
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
NCT02012218
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
NCT02013622
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
NCT02013531
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
NCT02013609
Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder
NCT01939353
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
NCT01994473
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
NCT01922258
PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
NCT01854944
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
NCT01940159
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
NCT01862640
Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
NCT01909466
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
NCT01683058
Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
NCT01727713
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
NCT01727726
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
NCT01710709
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
NCT01727700
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
NCT01668797
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
NCT01663532
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
NCT01702181
Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
NCT01567527
Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder
NCT01670279
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
NCT01711034
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
NCT01646827
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
NCT01552772
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
NCT01483183
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
NCT01416441
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
NCT01360866
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01451827
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
NCT01397786
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
NCT01432444
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
NCT01418352
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
NCT01418339
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
NCT01393613
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
NCT01396421
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
NCT01423916
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
NCT01149655
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
NCT01360645
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT01430494
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
NCT01360632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 45 |
| Phase 3 | 109 |
| Phase 4 | 10 |
Therapeutic Areas
What is open in the Otsuka Pharmaceutical Development & Commercialization pipeline
8 recruiting of 221 indexed (4% open); 186 completed (84%).
Phase mix: 119 late (III/IV) vs 97 early (I/II) (balanced across stages).
Top condition: Schizophrenia (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Otsuka Pharmaceutical Development & Commercialization: open-pipeline peers nationwide
Peers matched on 221 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Otsuka Pharmaceutical Development & Commercialization sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 221 trials (± recruiting share)
- National Eye Institute (NEI) · 221 trials · 8% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
Related
What to do with this Otsuka Pharmaceutical Development & Commercialization page
221 registered trials is a research-attention snapshot, not an endorsement of Otsuka Pharmaceutical Development & Commercialization or any single study.
- 8 of Otsuka Pharmaceutical Development & Commercialization's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Otsuka Pharmaceutical Development & Commercialization studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Otsuka Pharmaceutical Development & Commercialization pipeline card: 221 registered trials from official public datasets.Report a data error.